Drugs / FT536
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07560865 | Apr 2026 → Jun 2028 expected | astrocytoma (excluding glioblastoma), glioblastoma | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
| Phase 1 | NCT06342986 | Jul 2024 → Mar 2026 overdue | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Masonic Cancer Center, University of Minnesota | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05395052 | May 2022 → Aug 2023 | breast cancer, colorectal cancer, gastroesophageal cancer, head and neck cancer +3 | Fate Therapeutics | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-01-10 | Fate Therapeutics | Regulatory Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors fatetherapeutics.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-01-10 | Fate Therapeutics | Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors fatetherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT536 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05395052 ↗ |
| Modality | Cell therapy | “FT536 is an allogeneic natural killer (NK)-cell immunotherapy” NCT05395052 ↗ |